Company intelligence / Profile preview

Rasna Therapeutics

United States

Ownership: Public · RASP
Development stage: Preclinical

Overview

Rasna Therapeutics was a biotechnology company focused primarily on developing novel therapeutics for acute myeloid leukemia and other leukemias. The company's approach centered around small molecule drugs targeting epigenetic mechanisms implicated in these cancers. As per the most recent public information, their programs were at preclinical or early clinical stages with no reported late-stage trial results or approved products.

Therapeutic areas: OncologyHematology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

RASP-101

Pre-clinical

Indications: Acute myeloid leukemia

2 more assets in the full pipeline.

Request access →

Financials

Market cap: $385.9K
Total revenue: $0
Enterprise value: $688.5K

Beyond the preview

Go deeper on Rasna Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rasna Therapeutics.

Explore the full profile